Alamar Biosciences wants $159 million from public markets, pricing 9.4 million shares at $15 to $17 apiece for a Nasdaq listing under “ALMR.”
What do IPO investors actually get? The lead asset is Argo HT, a commercial-stage automated protein analyzer that’s capable of processing up to 288 samples per batched run with multiplexing support across multiple biomarker profiling tasks. Alamar launched it commercially in 2024 alongside NULISAseq, an inflammation panel for characterizing responses to autoimmune disorders, neurodegenerative diseases, cardiovascular disease, and cancer.
The revenue story doesn’t undercut the pitch. Alamar pulled in $74 million in sales last year, a 196% year-over-year jump per the SEC filing. For a company founded in 2018, that’s a credible commercial ramp. Its oversubscribed 2024 Series C raised $128 million, already demonstrating institutional appetite before a single public share was priced.
This IPO lands inside a crowded 2026 window. Seaport Therapeutics and Hemab Therapeutics have filed their own IPOs this year, and life sciences public offerings are accelerating after a slow stretch. Whether the market prices Argo HT as a pure instrument play or as a broader proteomics platform will determine where the stock actually opens.
— Diana Kowalski